For instance, BEs have been successfully applied in patient-derived organoid (PDO) models targeting mutations in KRAS and TP53. In PDOs of pancreatic ductal adenocarcinoma, efficient correction of the KRAS G12D was achieved, with an editing frequency of 30%. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.